XGN

Exagen Inc.

Healthcare · $205M market cap

We can't put a fair value on XGN right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?

Equity per share growth-36.9% a year✗

Sales growth13.8% a year✓

Free cash flow growth—?

Return on invested capital-40.3%✗

Follow XGN

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds XGN. In Q2 2026, 1 added. Who we track

First Eagle Investment Management

First Eagle Investment Management · as of Q2 2026

$1.4M

306,965 shares

Moves in Q2 2026

Added: First Eagle Investment Management

Insider activity

Since Sep 1, 2026: no open-market purchases, 1 sale worth $149K and 1 other filing (stock awards, tax withholding and similar). Why purchases matter

Sales

Black Jeffrey G.

Chief Financial Officer · 2026-09-01

Sold

$149K

Other filings

Black Jeffrey G.

Chief Financial Officer · 2026-09-01

Award

$5K

About Exagen Inc.

Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lupus erythematosus…

Medical - Diagnostics & Research